Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BROOKLYN study of obicetrapib in adults with heterozygous familial hypercholesterolemia
NL-OMON53451Phase 3Recruiting
- Sponsor
- NewAmsterdam Pharma
- Start
- Jan 2023
- Modality
- Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in familial hypercholesterolemia (FH) and hypercholesterolemia comparing Obicetrapib 10 mg with Placebo (2 arms). Primary endpoint: Percent change in fasting LDL-C at Day 84. Started Jan 2023; status: recruiting.
02
Drugs
obicetrapib
03
Conditions
familial hypercholesterolemia (FH)hypercholesterolemia
Beyond the preview
Go deeper on NL-OMON53451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53451.